Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer as of September 2022

MARA Rating Company December 16, 2025

Atogepant for preventing migraine as of May 2024

MARA Rating Company December 16, 2025

Nexviadyme / avalglucosidase alfa for treating Pompe disease as of August 2022

MARA Rating Company December 16, 2025

Avapritinib for treating advanced systemic mastocytosis as of November 2024

MARA Rating Company December 16, 2025

Avatrombopag for treating primary chronic immune thrombocytopenia as of December 2022

MARA Rating Company December 16, 2025

Avelumab for treating metastatic Merkel cell carcinoma as of April 2021

MARA Rating Company December 16, 2025

Avelumab for untreated metastatic Merkel cell carcinoma as of April 2021

MARA Rating Company December 16, 2025

Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy as of May 2022

MARA Rating Company December 16, 2025

Yescarta / axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies as of February 2023

MARA Rating Company December 16, 2025

Yescarta / axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma after 3 or more systemic treatments as of June 2023

MARA Rating Company December 16, 2025